Clinical trials
Completed Head and Neck Neoplasms trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 1 |
| 2017 | 6 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 48 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Technische Universität Dresden | 4 |
| AstraZeneca | 3 |
| Bristol-Myers Squibb | 2 |
| Charite University, Berlin, Germany | 2 |
| Eli Lilly and Company | 2 |
| Genentech, Inc. | 2 |
| Kura Oncology, Inc. | 2 |
| Sanofi | 2 |
| University Hospital Heidelberg | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Head and Neck Neoplasms | 48 |
| Squamous Cell Carcinoma of Head and Neck | 11 |
| Colorectal Neoplasms | 5 |
| Recurrence | 4 |
| Thyroid Neoplasms | 4 |
| Carcinoma, Medullary | 3 |
| Colonic Neoplasms | 3 |
| Neoplasm Metastasis | 3 |
| Thyroid Cancer, Papillary | 3 |
| Adenocarcinoma, Follicular | 2 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.